Blood Res.  2014 Dec;49(4):246-252. 10.5045/br.2014.49.4.246.

Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience

• Han JY
• Suh JK
• Lee SW
• Koh KN
• Im HJ
• Seo JJ

• KMID: 2270682
• DOI: http://doi.org/10.5045/br.2014.49.4.246

Abstract

BACKGROUND
Anaplastic large cell lymphoma (ALCL) is uncommon in children, accounting for approximately 15% of all cases of childhood non-Hodgkin lymphoma. Despite many studies attempting new treatment strategies, treatment outcomes have not significantly improved, and the optimal treatment for pediatric ALCL has not been established.
METHODS
The records of newly diagnosed ALCL patients at our institute between July 1998 and April 2013 were reviewed. We evaluated the general characteristics of the patients, chemotherapy regimens, overall survival (OS) rates, and event-free survival (EFS) rates.
RESULTS
Twenty-eight ALCL patients were eligible. The median age at diagnosis was 10.8 years. Lymph node involvement was the most common presentation (79%). CCG-5941, a multi-agent T-cell lineage chemotherapy, was the predominant treatment regimen (57%). The five-year OS and EFS rates were 88% and 69%, respectively. Stage, the presence of B symptoms, lung involvement, and bone marrow involvement were significant prognostic factors for EFS (P=0.02, 0.01, 0.01, and 0.02, respectively). Eight patients relapsed, and three died during the study period. Four of the eight patients who relapsed were treated with high-dose chemotherapy and autologous stem cell transplantation (HDCT-ASCT). Two of the four who had undergone HDCT-ASCT developed secondary relapses and were subsequently treated with allogeneic SCT or brentuximab.
CONCLUSION
We found that treatment outcomes with multi-agent chemotherapy in children with ALCL were similar to those of previous reports, and that relapsed patients could be salvaged with HDCT-ASCT or allogeneic SCT. A prospective, larger cohort study is warranted to define the optimal treatment for pediatric ALCL.

Keyword

Anaplastic large cell lymphoma; Childhood; Prognosis; Relpase

MeSH Terms

Bone Marrow
Child*
Cohort Studies
Diagnosis
Disease-Free Survival
Drug Therapy
Humans
Lung
Lymph Nodes
Lymphoma, Large-Cell, Anaplastic*
Lymphoma, Non-Hodgkin
Prognosis
Recurrence
Stem Cell Transplantation
T-Lymphocytes

Figure

• 

  Fig. 1 Overall survival (OS) and event-free survival (EFS) rates of 28 patients with anaplastic large cell lymphoma (A). OS and EFS rates of eight relapsed patients (B).

Reference

1. Pillon M, Gregucci F, Lombardi A, et al. Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Pediatr Blood Cancer. 2012; 59:828–833. PMID: 22389307.

2. Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children's Cancer Study Group. J Clin Pathol. 1997; 50:128–134. PMID: 9155693.

3. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988; 130:59–70. PMID: 2827494.

4. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96:3681–3695. PMID: 11090048.

5. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988; 1:292–293. PMID: 2893097.

6. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification-from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 2000; 11(Suppl 1):3–10. PMID: 10707771.

7. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009; 523–531. PMID: 20008237.

8. Wrobel G, Mauguen A, Rosolen A, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011; 56:1071–1077. PMID: 21280197.

9. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol. 1994; 12:899–908. PMID: 8164040.

10. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001; 97:3699–3706. PMID: 11389005.

11. Banavali SD, Goyal L, Bhagwat RV, et al. Vinblastine based short-pulse B-non-Hodgkin’s lymphoma type chemotherapy (CT) with maintenance therapy is highly efficacious treatment for anaplastic large cell lymphoma (ALCL). Blood. 2006; 108(ASH Annual Meeting):abst 4673.

12. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005; 104:2133–2140. PMID: 16211546.

13. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005; 23:541–547. PMID: 15659500.

14. Lowe EJ, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Childrens Cancer Group Study 5941. Pediatr Blood Cancer. 2009; 52:335–339. PMID: 18985718.

15. Dokmanovic L, Krstovski N, Vukanic D, et al. Pediatric non-Hodgkin lymphoma: a retrospective 14-year experience with Berlin-Frankfurt-Münster (BFM) protocols from a tertiary care hospital in Serbia. Pediatr Hematol Oncol. 2012; 29:109–118. PMID: 22376014.

16. Garner R, Li Y, Gray B, et al. Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine. J Pediatr Hematol Oncol. 2009; 31:145–147. PMID: 19194204.

17. Yared J, Kimball A. The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev. 2013; 39:51–59. PMID: 22541889.

18. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type firstline therapy: a BFM-group study. J Clin Oncol. 2011; 29:3065–3071. PMID: 21709186.

19. Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010; 16:223–230. PMID: 19800015.

20. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkins lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012; 97:310–317. PMID: 21993674.

21. Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J. 2012; 18:450–456. PMID: 23006951.

22. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013; 98:611–614. PMID: 23065511.

23. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14:472–480. PMID: 23598171.

24. Park KD, Shin HY, Ahn HS. Childhood Ki-1 lymphoma: clinical features and treatment outcome. Korean J Hematol. 1995; 30:455–462.

25. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7:332–339. PMID: 7414342.

26. Uckun FM, Nachman JB, Sather HN, et al. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma. 1999; 33:101–106. PMID: 10194126.

27. Heath JA, Steinherz PG, Altman A, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol. 2003; 21:1612–1617. PMID: 12697887.

28. Mora J, Filippa DA, Qin J, Wollner N. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer. 2003; 98:1283–1291. PMID: 12973853.

29. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008; 111:1560–1566. PMID: 17957029.

30. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006; 133:176–182. PMID: 16611309.